Self-report of post-vaccination adverse events against COVID-19 by health workers at a university hospital
DOI:
https://doi.org/10.30968/rbfhss.2023.144.0914Abstract
Objective: To describe the adverse event profile of vaccines against Covid-19 administered to workers at a university hospital. Methods: An observational, longitudinal monitoring study of adverse events following immunization identified and reported through a self-report form was carried out. An adverse event following immunization self-report form was prepared in the Microsoft Office and made available via a link for access and completion from the beginning of the vaccination campaign in Brazil. The disclosure of the self-report form was carried out at the beginning of the campaigns for the first, second and third dose of vaccines against COVID-19, through the institutional email, publication of posters with access to the form via QR code on the intranet and sharing through the WhatsApp application in the groups of the Institution. At first, stimulated passive surveillance of adverse events related to the COVID-19 vaccine was performed. From February 2021, when the administration of the 2nd dose was started, in addition to stimulated passive surveillance, an active search for adverse events following immunization was carried out. Descriptive statistics were used for data analysis by calculating the absolute and relative frequencies for categorical variables and measures of central tendency to calculate continuous variables. Results: 225 adverse events following immunization records involving the Oxford/Covishield (Fiocruz e Astrazeneca), Coronavac (Butantan), Comirnaty (Pfizer/Wyeth) vaccines were included in this study. Local adverse events were more frequent in the third dose and systemic in the first dose. Pain, induration and swelling were the most common local symptoms. Systemic included fatigue, headache, muscle pain and fever. Conclusion: The use of the vaccination strategy against Covid-19 in our population proved to be a safe strategy to face the pandemic.
Downloads
References
Khan M, Adil SF, Alkhathlan HZ, et al. COVID-19: A Global Challenge with Old History, Epidemiology and Progress So Far. Molecules. 2021, 26(1):39. https://dx.doi.org/10.3390/molecules26010039. DOI: 10.3390/molecules26010039
To KK, Sridhar S, Chiu KH, et al. Lessons learned 1 year after SARS-CoV-2 emergence leading to COVID-19 pandemic. Emerg Microbes Infect. 2021 Dec;10(1):507-535. Doi: 10.1080/22221751.2021.1898291.
Brito SBP, Braga IO, Cunha CC, et al. Pandemia da COVID-19: o maior desafio do século XXI. Vigil. sanit. debate 2020;8(2):54- 63. DOI: https://doi.org/10.22239/2317-269X.01531.
Uzunian A. Coronavirus SARS-CoV-2 and Covid-19. J Bras Patol Med Lab [Internet]. 2020;56:e3472020. Available from: https://doi.org/10.5935/1676-2444.20200053.
Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Agência Nacional de Vigilância Sanitária. Protocolo de vigilância epidemiológica de eventos adversos pós-vacinação. Estratégia de vacinação contra o vírus SARSCoV- 2 (Covid19- Brasília: Ministério da Saúde, 2020a.
Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de Imunizações e Doenças Transmissíveis. Manual de vigilância epidemiológica de eventos adversos pós-vacinação [recurso eletrônico] / Ministério da Saúde, Secretaria de Vigilância em Saúde, Departamento de Imunizações e Doenças Transmissíveis. – 4. ed. – Brasília: Ministério da Saúde, 2020b. 340 p.: il.
OPAS. Manual de vigilância de eventos supostamente atribuíveis à vacinação ou imunização na Região das Américas. Washington, D.C.: Organização Pan-Americana da Saúde; 2022. Licença: CC BY-NCSA 3.0 IGO. https://doi. org/10.37774/9789275723869.
Wu Z, Hu Y, Xu M, et al. Safety, tolerability, and immunoge- nicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21(6):803-812. Doi: 10.1016/ S1473-3099(20)30987-7.
Santos CF, Ariente M, Diniz MVC, et al. O processo evolutivo References entre as gerações X, Y e Baby Boomers. In: Seminário em administração FEA-USP, XIV, 2011, São Paulo. Anais... São Paulo: SEMEAD, 2011.
Banerji A, Wickner PG, Saff R, et al. mRNA Vaccines to Prevent COVID-19 Disease and Reported Allergic Reactions: Current Evidence and Suggested Approach. J Allergy Clin Immunol Pract. 2020;9(4):1423-37.
Sokolowska M, Eiwegger T, Ollert M, et al. EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID-19 vaccines. Allergy. 2021 Jun;76(6):1629- 1639. Doi: 10.1111/all.14739.
Patel R, Kaki M, Potluri VS, et al. A comprehensive review of SARS-CoV-2 vaccines: Pfizer, Moderna & Johnson & Johnson. Hum Vaccin Immunother. 2022 Dec;18(1):2002083. doi: 10.1080/21645515.2021.2002083.
Ramasamy MN, Minassian AM, Ewer KJ, et al. Oxford COVID Vaccine Trial Group. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet 2020; 396: 1979–93. https://doi.org/10.1016/S0140-6736(20)32466-1.
Alhumaid S, Mutair A, Alawi Z, et al. Anaphylactic and nonanaphylactic reactions to SARS-CoV-2 vaccines: a system- atic review and meta-analysis. Allergy Asthma Clin Immunol. 2021 Oct 16;17(1):109. doi: 10.1186/s13223-021-00613-7.
Silva RB da, Silva TPR da, Sato APS, Lana FCF, Gusmão JD, Souza JFA, Matozinhos FP. Adverse events following immunization against SARS-CoV-2 (covid-19) in the state of Minas Gerais. Rev saúde pública. 2021; 22;55:66. Available from: https://www.revistas.usp.br/rsp/article/view/191771.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Authors
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The authors hereby transfer, assign, or otherwise convey to RBFHSS: (1) the right to grant permission to republish or reprint the stated material, in whole or in part, without a fee; (2) the right to print republish copies for free distribution or sale; and (3) the right to republish the stated material in any format (electronic or printed). In addition, the undersigned affirms that the article described above has not previously been published, in whole or part, is not subject to copyright or other rights except by the author(s), and has not been submitted for publication elsewhere, except as communicated in writing to RHFHSS with this document.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC-BY-NC-ND) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Serlf-archiving policy
This journal permits and encourages authors to post and archive the final pdf of the articles submitted to the journal on personal websites or institutional repositories after publication, while providing bibliographic details that credit its publication in this journal.